RxDoctor Payments Data

Leah Macklin, DO

Family Medicine · Cumming, GANPI 1184004103

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 121 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$350
  • Astellas Pharma US Inc$292
  • AstraZeneca$226
  • Amgen$168
  • Novo Nordisk$150
  • Neos Therapeutics, LP$149
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,29993%
  • Education$1797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,478 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$74,856
Medicare patients
108
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol39$37,043
OzempicSemaglutide12$27,409
MounjaroTirzepatide24$23,229
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,758
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,390
ValacyclovirValacyclovir Hcl15$1,371
SynthroidLevothyroxine Sodium19$1,302
Duloxetine Hcl43$794
Levothyroxine Sodium78$754
Bupropion XlBupropion Hcl35$723
Gabapentin39$684
Famotidine47$651
Olmesartan Medoxomil28$584
Atorvastatin Calcium71$557
Rosuvastatin Calcium73$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$226$37,04339 claims
Novo NordiskOzempic$150$27,40912 claims
Lilly USA, LLCMounjaro$98$23,22924 claims
GSKTrelegy Ellipta, Shingrix$39$17,14844 claims
AbbVieSynthroid$350$1,30219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →